Moving advanced healthcare technology from the laboratory to the clinic necessarily requires the support of a commercial organisation to effect the transition.
For that reason the Cancer Diagnostic Technology Summit includes presentations by both academic and industry speakers.
LIquid biopsy, in which a sample of blood or other fluid, is examined for cancer biomarkers, offers most hope for a low cost, accessible cancer screening tool. The technology, which is developing rapidly, can provide multi-test platforms to identify several cancer types in a single sample.
Among Speakers on Liquid Biopsy at CDT21 on 11th May are:
Sara Hiom, GRAIL Europe: Multi-cancer early detection
Dr, Heather Parsons MD, Dana Farber Cancer Institute: Detecting minimal residual disease in breast cancer
Dr. Sylvain Ladame, Imperial College: Detecting nucleic acid biomarkers at the point of care
Dr. Rui Campos, University of Antwerp: Electrochemiluminescent assay for prostate cancer
The conference also includes sessions on: VOC Biomarkers; The Pathway to Early Diagnosis; Cell Separation; Advanced Technology in Cancer Detection; Imaging: AI in Clinical Judgement.